Amerant Bancorp (NASDAQ:AMTB – Get Free Report) was upgraded by equities research analysts at Stephens from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a $25.00 target price on the stock, up from their previous target price of $24.00. Stephens’ target price would suggest a potential upside of 23.15% from the stock’s previous close.
Several other equities research analysts also recently weighed in on AMTB. Keefe, Bruyette & Woods cut their price target on Amerant Bancorp from $26.00 to $24.00 and set a “market perform” rating on the stock in a report on Monday, July 29th. Piper Sandler upgraded Amerant Bancorp from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $26.00 to $26.50 in a report on Monday. Finally, Janney Montgomery Scott downgraded Amerant Bancorp from a “buy” rating to a “neutral” rating and set a $25.00 price target on the stock. in a report on Friday, July 26th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.50.
Amerant Bancorp Price Performance
Amerant Bancorp (NASDAQ:AMTB – Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.07). Amerant Bancorp had a return on equity of 7.78% and a net margin of 3.15%. The company had revenue of $98.78 million for the quarter, compared to analysts’ expectations of $93.19 million. During the same quarter last year, the company earned $0.24 EPS. On average, sell-side analysts anticipate that Amerant Bancorp will post 1.33 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in AMTB. Charles Schwab Investment Management Inc. boosted its position in shares of Amerant Bancorp by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 207,699 shares of the company’s stock worth $5,103,000 after acquiring an additional 2,649 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Amerant Bancorp by 9.4% in the 4th quarter. Wellington Management Group LLP now owns 3,113,483 shares of the company’s stock valued at $76,498,000 after purchasing an additional 267,466 shares during the period. Salzhauer Michael boosted its position in shares of Amerant Bancorp by 66.7% in the 1st quarter. Salzhauer Michael now owns 24,988 shares of the company’s stock valued at $582,000 after purchasing an additional 10,000 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Amerant Bancorp by 89.8% in the 1st quarter. BNP Paribas Financial Markets now owns 13,234 shares of the company’s stock valued at $308,000 after purchasing an additional 6,261 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Amerant Bancorp by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 1,619,150 shares of the company’s stock valued at $37,710,000 after purchasing an additional 10,835 shares during the period. 42.11% of the stock is owned by institutional investors and hedge funds.
About Amerant Bancorp
Amerant Bancorp Inc operates as the bank holding company for Amerant Bank, N.A. that provides banking products and services to individuals and businesses in the United States and internationally. It offers checking, savings, business, and money market accounts; cash management services; and certificates of deposits.
Featured Stories
- Five stocks we like better than Amerant Bancorp
- What is the S&P 500 and How It is Distinct from Other Indexes
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Roth IRA Calculator: Calculate Your Potential Returns
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Amerant Bancorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amerant Bancorp and related companies with MarketBeat.com's FREE daily email newsletter.